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Quality of life (QOL) is generally deﬁned as a multidimensional
construct related to ‘‘individuals’ perceptions of their position in
life, in particular to their goals, expectations, standards and con-
cerns” [1]. Health-related quality of life (HRQOL) adds to the previ-
ous elements the clinical dimensions; in epilepsy, it is based
mainly on emotional and social functions and disease-related
variables.
The impact of epilepsy on HRQOL has been repeatedly empha-
sized over time [2]. Several reports from industrialized and devel-
oping countries indicate that HRQOL is signiﬁcantly worse in
people with epilepsy than in the general population [3–6] or peo-
ple with other chronic clinical conditions [7].
HRQOL in epilepsy can be evaluated with generic or epilepsy-
speciﬁc instruments, or a combination. Generic measurementsll rights reserved.
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comparisons across patients affected by different pathologies and
between patients and controls. The Sickness Impact Proﬁle (SIP)
[8], the Dartmouth Coop Charts [9], and the Medical Outcomes
Study (MOS) [10] are some of the most frequently applied generic
questionnaires. Epilepsy-speciﬁc measurements, on the contrary,
focus on issues relevant to this disease, on its symptoms and other
aspects related to treatments, and, therefore, are more sensitive to
the uniqueness of epilepsy. The ESI-55 [11], Liverpool Battery [12],
QOLIE-89 [13], QOLIE-10 [14], and QOLIE-31 [15] are among the
most representative existing epilepsy-speciﬁc questionnaires.
Leone and co-workers described in a recent study the state-of-
the-art measurement of QOL in epilepsy and discussed the most
suitable instruments for clinical or research purposes [16].
Very few validated Italian generic questionnaires are available
for the evaluation of QOL in adults [17–20]; there is only one
epilepsy-speciﬁc measure, an adaptation of the QOLIE-31 inven-
tory [21], which is reported in the literature. However, none of
these instruments (including the QOLIE-31) were felt to satisfacto-
rily address the needs and expectations of Italian patients with
epilepsy and their physicians. Indeed, QOL measures strongly re-
ﬂect the social and cultural background of a population. We thus
presumed that a new epilepsy-speciﬁc Italian HRQOL question-
naire was necessary; therefore, the decision was made to develop
a new instrument, the Epi-QoL, and to validate it through a
multicenter study. Our instrument is not an adaptation of an al-
ready existing measure, but represents the ﬁrst QOL questionnaire
Table 1
Demographic and clinical characteristics of the study population (N = 815)
N %
Geographic distribution
Northern Italy 320 39.2
Central Italy 267 32.8
Southern Italy 228 28.0
Age 38.2 ± 14.2a
Gender (F/M) 422/393 52/48
Education
68 years 315 38.7
9–13 years 358 43.9
P14 years 142 17.4
Marital status
Single 377 46.3
Married 416 51.0
Separate 16 2.0
Widower/widow 6 0.7
Occupation
White-collar workers 164 20.1
Housewives 143 17.5
Blue-collar workers 108 13.3
Unemployed 60 7.4
Other 340 41.7
Epilepsy syndromes
Focal epilepsy 606 74.3
Generalized epilepsy 181 22.2
Undetermined epilepsies and syndromes 25 3.1
Special syndromes 3 0.4
Seizure type
Focal 598 73.4
Generalized 209 25.6
Mixed 8 1.0
Seizure frequency in preceding 12 months
0 324 39.8
1–5 208 25.5
6–20 106 13.0
>20 177 21.7
Seizure frequency in preceding 2 weeks
0 560 68.7
1–5 191 23.4
6–20 43 5.3
>20 21 2.6
Etiology
Symptomatic 326 40.0
Cryptogenic 311 38.2
Idiopathic 178 21.8
Disease duration (years) 19.0 ± 13.2a
Disease duration at diagnosis (years) 17.1 ± 12.9a
Age at onset of seizures (years) 20.0 ± 15.3a
Prognostic category
Newly diagnosed epilepsy 32 3.9
2+ years of remission 246 30.2
1+ years of remission 189 23.2
Non-drug-resistant seizures 165 20.3
Drug-resistant seizure 160 19.6
Surgical candidates 23 2.8
Presence of relevant comorbidity 148 18.2
Number of medications
Monotherapy 441 54.1
Polytherapy 361 44.3
No therapy 13 1.6
Adverse treatment events
Yes 123 15.1
No 692 84.9
Intellectual functions
Normal 704 86.4
Compromised 111 13.6
Psychiatric disturbances
Yes 107 13.1
No 708 86.9
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and productively used by clinicians and researchers.
The aims of the present study were to evaluate this new instru-
ment, verify its psychometric properties, and investigate the main
clinical variables affecting the total HRQOL score.
2. Methods
2.1. Subjects
Twenty-four secondary and tertiary Italian centers for the care of epilepsy par-
ticipated in the study. To be included, patients from each center had to meet the fol-
lowing criteria: age 18 or older; diagnosis of epilepsy (at least two unprovoked
seizures 24 hours apart) [22]; presence of idiopathic, cryptogenic, or symptomatic
epilepsy according to the ILAE syndromic classiﬁcation [23]; good compliance with
treatment and study participation; informed consent; and ability to read and
understand the questions.
Each center was asked to recruit up to 30 patients. We admitted into the study
consecutive patients seen in the ambulatory setting and meeting the above-men-
tioned criteria. For each eligible patient, a number of demographic and clinical vari-
ables were recorded in a semistructured form. Table 1 summarizes these data
(N = 815).
2.2. Measures
The Epi-Qol (see Appendix) was developed as a patient-based questionnaire to
be used as a speciﬁc measure of HRQOL in clinical practice in Italy. The items con-
stituting this measure were selected mainly on the basis of issues perceived impor-
tant to patients’ lives from the operators’ experiences, patients’ interviews, and
existing literature. An expert panel (composed of epileptologists and psychologists
working for at least 5 years at Italian epilepsy centers) identiﬁed six domains (Phys-
ical Functioning, Cognitive Functioning, Emotional Well-Being, Social Functioning,
Seizure Worry, Medication Effects) considered relevant for the population with
epilepsy.
The Epi-Qol is a 46-item self-administered questionnaire. Subjects have to rate
their HRQOL on a 6-point Likert scale format: ‘‘very frequently” (1), ‘‘very much”
(2), ‘‘quite enough” (3), ‘‘a bit” (4), ‘‘very little” (5), ‘‘not at all” (6).
For external validity, we chose to use the QOLIE-31, which is composed of six
similar domains and was standardized in Italy [21].The QOLIE-31 was administered
at the same time as the Epi-Qol.
Two weeks was chosen as the interval between the Epi-Qol test and retest to
minimize the subjects’ recall for the previous answers [3]. The operators from the
different centers who administered the questionnaire were trained in several meet-
ings, during which they learned homogeneous administration of the form.
2.3. Statistics
All the data collected were transferred into an electronic database and pro-
cessed using the SAS Statistical Package (SAS 8.2).
The internal consistency reliability of the new instrument was estimated with
Cronbach’s a coefﬁcient [24]. Spearman’s interitem correlation was also computed.
The mean Spearman correlation was calculated by employing Fisher’s z transforma-
tion [25].We decided to use Spearman’s correlations for all these analyses because
our data were non-normally distributed.
Test–retest reliability was determined by using intraclass correlation to measure
the proportion of total variation due to between-individual variability [26]. Con-
struct validity was analyzed by the relationship between domains and other exter-
nal measures (geographic distribution, seizure frequency in previous 12 months,
number of medications), considered a priori to be related to the domains. Discrim-
inant validitywas determined by evaluating the capacity of the instrument to differ-
entiate between groups with expected differences in HRQOL scores, by adopting
criteria from the literature [3]; thus, univariate F tests of scales and items with these
variables were computed [27].
The overall HRQOL score, obtained by summing the scores of each domain, ran-
ged between 46 and 276; the higher the score, the greater the QOL perceived, which
means that the answers to questions that were positively formulated (items 1, 3, 20,
23, and 36) had to be reversed to calculate the sum score.‘‘Poor” HRQOL was deﬁned
by a score lower than 161, ‘‘fair” HRQOL by a score ranging from 161 to 229, and
‘‘good” HRQOL by a score of 230 or higher. The ﬁrst group (‘‘poor”) comprised sub-
jects who scored mainly 1 or 2 (‘‘very frequently,” ‘‘very much”); the second group
(‘‘fair”) comprised those who scored mainly 3 or 4 (‘‘quite enough,” ‘‘a bit”); and the
third group (‘‘good”) comprised those who scored mainly 5 or 6 (‘‘very little,” ‘‘not
at all”).
The distribution of overall HRQOL scores was negatively skewed; the lower cut-
off point was deﬁned in such a way that ‘‘fair” HRQOL included subjects with aver-
age scores less than the expected value assuming a uniform distribution of single
items. The higher cutoff point was deﬁned to classify under ‘‘good” HRQOL all the
subjects with average scores of 5 or higher [26].
Table 1 (continued)
N %
Disability status
Yes 201 24.7
675% 108 13.3
>75% 93 11.4
No 614 75.3
a Mean ± SD.
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multivariate ANOVAs with stepwise-backward selection were performed, after data
transformation by rank normal scoring due to their strong negative asymmetry
[28].
3. Results
3.1. Descriptive statistics and reliability
Table 2 summarizes the descriptive statistics and the evaluation
of the reliability of our instrument. All domains showed strong
internal consistency reliability: Cronbach’s a was between 0.77
(Physical Functioning) and 0.89 (Social Functioning), the overall
Epi-QoL being 0.96. All these values exceeded the generally ac-
cepted criterion of 0.70 for adequate reliability for group compar-
isons [28]. The domains with the highest mean interitem
correlation were Seizure Worry and Cognitive Functioning.
For each domain, the percentage of correlations with values be-
tween 0.20 and 0.60 was always greater than 71.4, implying that
the items did not overlap and were correlated within the same
domains.4,1 4,2 4,3 4,4
Medication 
Emotion 
Fig. 1. Ninety-ﬁve percent conﬁdence intervals of mean score (dot) for each Epi-QoL d
Cognitive Functioning; Social, Social Functioning; Seizure, Seizure Worry; Medication, M
Table 2
Descriptive statistics and reliability
Domain No. of
items
Mean SD Floor/ceiling
effects (%)
Cronbac
a
Overall Epi-QoL 46 207.7 43.7 0/0 0.96
Physical Functioning 7 31.3 7.6 0/0 0.77
Emotional Well-Being 7 29.9 7.8 0.1/1.7 0.81
Cognitive Functioning 7 32.2 8.3 0.1/11.4 0.88
Social Functioning 12 55.6 12.8 0.1/3.4 0.89
Seizure Worry 8 37.4 9.2 0.2/12.8 0.86
Medication Effects 5 21.3 6.2 0/8.22 0.82
a Intraclass correlation coefﬁcients: ðd2b  d2wÞ=½d2b þ ðn 1Þd2w, where n = 2 as the num
within and between variances, respectively.
b Means were calculated using Fisher z transformation.
c P < 0.05.Test–retest data for patients who were clinically stable yielded
signiﬁcant correlations for all the domains, ranging from 0.38
(Emotional Well-Being) to 0.84 (Cognitive Functioning), indicating
good agreement and, consequently, consistent reliability of the
inventory.
Fig. 1 illustrates the relationship among the mean scores ad-
justed for the number of items constituting each domain, consider-
ing their 95% conﬁdence intervals. Seizure Worry, Social
Functioning, and Cognitive Functioning were comparable in terms
of mean scores, followed by Physical Functioning; on the contrary,
mean scores for Emotional Well-Being and Medication Effects were
signiﬁcantly lower.
3.2. Multitrait analysis
The internal correlations between different domains were all
signiﬁcant (P < 0.001), ranging between 0.5 (Physical Functioning,
Medication Effects) and 0.8 (Physical Functioning, Social Function-
ing). Thus, the domains constituting our total HRQOL score ap-
peared signiﬁcantly correlated, conﬁrming that they measured
similar components. In every instance, individual items correlated
more signiﬁcantly with the domain on which that item loaded than
with other domains.
3.3. Validity
Content validity was assessed by considering that the selection
of items constituting the questionnaire was based on speciﬁc in-
puts by a panel of experts and by patients, as well as on a review
of the literature. In this way it was possible to identify the most rel-
evant HRQOL issues in epilepsy [13].4,5 4,6 4,7 4,8
Physical 
Social 
Seizure
Cognitive 
omain. Physical, Physical Functioning; Emotion, Emotional Well-Being; Cognitive,
edication Effects.
h’s Intraclass
correlationa
Interitem correlation
(Spearman’s)
% Correlation between
0.2 and 0.6
Meanb min max
0.50c 0.37c 0.05 0.74 85.0
0.61c 0.38c 0.07 0.72 71.4
0.38c 0.39c 0.20 0.46 81.0
0.84c 0.54c 0.48 0.65 95.2
0.39c 0.43c 0.18 0.74 93.9
0.54c 0.55c 0.30 0.61 94.4
0.47c 0.31c 0.31 0.58 100.0
ber of replicated measurements of Epi-Qol, and d2b and d
2
w represent the estimated
Table 5
HRQOL scores by demographic and clinical characteristics of the study population
Variable Mean F P
Geographic distribution
Northern Italy 214.20 11.8 0.0006
Central Italy 210.76
Southern Italy 194.93
Gender
Female 202.60 11.2 0.0009
Male 213.14
Seizure frequency in preceding 12 months
0 227.37 9.2 0.0025
1–5 204.52
6–20 195.31
>20 182.85
Prognostic category
Newly diagnosed epilepsy 196.23 5.1 0.0242
2+ years of remission 230.09
1+ years of remission 213.22
Non-drug-resistant seizures 197.52
Drug-resistant seizures 182.83
Surgical candidate 183.65
Number of medications
Monotherapy 218.72 4.3 0.0373
Polytherapy 193.14
Relevant comorbidity
No 210.66 4.5 0.0337
Yes 194.28
Cognitive functions
Normal 211.16 6.0 0.0143
Compromised 185.49
Psychiatric disturbances
Yes 183.41 20.8 0.0001
No 211.33
Disability
No 215.15 24.4 0.0001
Yes 185.01
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tically signiﬁcant (Table 3). There was a negative correlation be-
tween geographic distribution, seizure frequency in the
preceding 12 months, and number of drugs and the Epi-Qol do-
mains: patients living in Northern Italy, those with a small number
of seizures, and those on monotherapy seemed to have better QOL.
Results for discriminant validity indicated that the best discrim-
inant factor, particularly in relation to Social Functioning and Phys-
ical Functioning, was seizure frequency in the preceding 2 weeks
(Table 4).
External validity demonstrated a good correlation (r = 0.64) be-
tween overall Epi-QoL and overall QOLIE-31 domains; furthermore,
the correlations between Cognitive Functioning, Emotional Well-
Being, Seizure Worry, Physical Functioning, and Medication Effects
in the two questionnaires were statistically signiﬁcant (P < 0.05).
On the contrary, the correlations between Social Functioning on
Epi-QoL and on QOLIE-31 were not signiﬁcant (P > 0.05), probably
because of the large number of missing values on the QOLIE-31 So-
cial Functioning scale [21].
3.4. Variables affecting HRQOL results
Self-reported HRQOL scores were ‘‘good” in 38.7%, ‘‘fair” in
44.9%, and ‘‘poor” in 16.4% of the sample.
Of the 18 variables having inﬂuence on HRQOL (i.e., geographic
distribution, age, gender, education, marital status, epilepsy syn-
dromes, seizure type, seizure frequency in preceding 12 months,
etiology, disease duration, age at onset, prognostic categories,
comorbidity, number of medications, adverse treatment events,
intellectual function, psychiatric disturbances, disability), 9 af-
fected HRQOL signiﬁcantly (geographic distribution, gender, sei-
zure frequency, prognostic categories, number of medications,
relevant comorbidity, presence of cognitive impairment, psychiat-
ric disturbances, and disability) (Table 5).
Scores varied signiﬁcantly with prognostic category, being high-
est in patients with epilepsy in remission and lowest in patients
with drug-resistant epilepsy and surgical candidates. Patients with
newly diagnosed epilepsy scored worse than patients with well-
controlled seizures and scored equal to patients with persisting
(non-drug-resistant) seizures.
Fig. 2 illustrates the frequencies of the Epi-Qol scores for each
domain separately by prognostic category. With few exceptions,Table 3
Construct validity: Spearman’s correlations between Epi-QoL domains and selected extern
Domain
Overall
Epi-QoL
Physical
Functioning
Emotional
Well-Being
Geographic distribution 0.16a 0.09a 0.16a
Seizure frequency in preceding
12 months
0.41a 0.39a 0.35a
Number of medications 0.31a 0.31a 0.25a
a P < 0.001.
Table 4
Discriminant validity: Univariate F test
Domain
Overall
Epi-QoL
Physical
Functioning
Em
We
Seizure frequency in preceding 2 weeks 58.9a 46.9a 37.
Seizure type 14.7a 19.5a 10.
Prognostic category 37.8a 31.0a 23.
a P < 0.001.
b P < 0.05.for each domain, patients in remission for 2+ years scored the high-
est, followed by patients in remission for 1+ years, patients with
persisting non-drug-resistant seizures, patients with newly diag-
nosed epilepsy, patients with drug-resistant epilepsy, and surgical
candidates.al variables
Cognitive
Functioning
Social
Functioning
Seizure
Worry
Medication
Effects
0.05a 0.13a 0.23a 0.13a
0.27a 0.41a 0.35a 0.23a
0.20a 0.34a 0.23a 0.17a
otional
ll-Being
Cognitive
Functioning
Social
Functioning
Seizure
Worry
Medication
Effects
1a 21.7a 55.2a 43.4a 15.6a
3b 9.12b 14.3a 5.4b 4.3a
2a 13.81a 36.6a 24.2a 10.5a
020
40
60
80
1 2 3 4 5 6
Good
Fair
Poor
% 
Fig. 2. Overall HRQOL scores and prognostic categories. (1) Newly diagnosed epi-
lepsy; (2) 2+ years of remission; (3) 1+ years of remission; (4) non-drug-resistant
seizures; (5) drug-resistant seizures; (6) surgical candidate.
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We have reported the reliability and validity of a new question-
naire measuring HRQOL, the Epi-QoL. Its psychometric properties
seem fairly good; thus, this questionnaire can be considered a valid
and sensitive epilepsy-targeted measure, designed to assess
HRQOL in a broad spectrum of Italian adults with epilepsy.
In this study most of the patients attained ‘‘fair” QOL scores, fol-
lowed in order by ‘‘good” and ‘‘poor” scores. This is in line with
other reports: the majority of patients with epilepsy perceive
themselves as having medium-to-good general life satisfaction;
only a few believe that epilepsy has a very detrimental effect on
their lives [29].
Numerous factors signiﬁcantly affected the HRQOL scores, as re-
ported; in particular, lower values were noted for living in South-
ern Italy, female gender, seizure frequency, prognostic categories,
use of polytherapy, as well as presence of cognitive impairment,
psychiatric disturbances, comorbidity, and disability.
Stigmamayperhaps explain the role played inHRQOLby living in
Southern Italy, a placewhere having epilepsymaymean beingmore
isolated for sociocultural reasons [30]. Prejudiceassociatedwithepi-
lepsy and the social norms and practices that still surround it can be
very strong in Southern Italy and, togetherwith a difﬁcult economic
situation, can negatively impact the quality of life perceived by pa-
tients with epilepsy [30].
Previous investigations have noted that compared with men,
women more frequently have emotional difﬁculties or distress
and lower self-esteem [31]. Upton and Thompson reported similar
results, with females with epilepsy having poorer self-esteem than
their male counterparts [32]. Other authors have conﬁrmed the
lower psychological well-being of women in other chronic medical
conditions [33]. These ﬁndings can be in part responsible for the
impaired HRQOL reported by women in this study.
The frequency of seizures seems to be a central factor in
HRQOL: living with recurring seizures—experiencing the uncertain
and unpredictable nature of epilepsy—certainly does affect per-
sonal psychological status, behavior, and mood [34]. Patients with
seizures feel unprotected, uncomfortable, worried, and disap-
pointed and can encounter difﬁculties with peers in personal rela-
tionships, in the workplace, and in other social networks [35–37].
Prognostic categories represent another relevant variable that
can have an impact on the HRQOL of patients: those whose sei-
zures are medication resistant and those who are candidates for
neurosurgery are particularly inclined to complain about their per-
sonal well-being.
Polytherapy has often been associated with important side ef-
fects, which can inﬂuence patients’ cognition and their psycholog-ical and psychiatric proﬁles. Long-term polytherapy may affect
higher-order cortical functions: an increased number of antiepilep-
tic medications can provoke cognitive slowness, memory impair-
ment, and attention and language deﬁcits, which, in turn, can
lead to negative social restrictions [38].
Some drugs used in polytherapy can also inﬂuence the psychi-
atric status of patients, especially their mood [39]. Mood has
repeatedly been found to be one of the strongest predictors of poor
HRQOL in epilepsy [40–44]. Perrine et al. suggested that the abnor-
malities of the mood state are strictly related to unsatisfactory life
fulﬁllment; it has been noted that mood factors can exert inﬂuence
on patients’ perceptions and on self-reporting of cognitive abilities
[45]. Mood really represents a key factor, and the study of its rela-
tionship to overall QOL should be very helpful [46]. In particular,
we believe that future investigations on this topic should focus
on the inﬂuence of mood, as an independent factor, on overall QOL.
Comorbidity and disability contributedmore to determine nega-
tive connotations across patients with epilepsy; Miller and col-
leagues indicated that the association of comorbidity with epilepsy
signiﬁcantly reducedpatients’ satisfactionwith life [47]. Seizure fre-
quency, polytherapy, cognitive impairment, psychiatric distur-
bances, mood, comorbidity, and disability may all depend on
complex and multifactorial interactions across biological, psycho-
logical, and social variables. These factors aggravate the degree of
impairment connected with other important consequences of epi-
lepsy, such as restrictions on driving, reduced fertility, low percent-
ageofmarriage, highunemployment, and lack of independence [48].
Other variables, such as duration of the disorder and age at on-
set of epilepsy did not signiﬁcantly contribute to the HRQOL score,
as highlighted by others [29]. These different results could be as-
cribed to the different methodologies employed, for example, dif-
ferent questionnaires, sample selection criteria, and types of
epilepsy cohorts.
Patients with drug-resistant epilepsy and surgical candidates
reported worse QOL. This is not an unexpected ﬁnding. QOL scores
have been shown to improve when seizures are reduced, both with
antiepileptic drugs and with neurosurgery [49]. Other studies have
demonstrated a positive correlation between the degree of seizure
improvement after surgery and HRQOL scores [50–53].
The QOL of patients with newly diagnosed epilepsy seemed
slightly better than that of patients with severe epilepsy, but worse
than that of patients with satisfactory seizure control. These ﬁnd-
ings agree with those in other reports [43,54–57] and are consis-
tent with the repeated observation of HRQOL improvement after
seizure reduction [58]. As clearly indicated by Jacoby and co-work-
ers [59], about a quarter of patients newly diagnosed with epilepsy
report feeling stigmatized as compared with 14% of patients with
seizures in remission for at least 2 years.
This study has some strengths and limitations. Our instru-
ment exhibits valid psychometric properties, and this is one
of the largest surveys of HRQOL in people with epilepsy. A lim-
itation concerns the lack of comparative features from the Ital-
ian population.
We believe that there was a need to develop a new comprehen-
sive Italian HRQOL-speciﬁc measure that can be used in the adult
epilepsy population. This instrument, which is simple and easy to
administer, can contribute to a better understanding of the impact
of epilepsy on patients’ perceptions, beyond the occurrence of sei-
zures, to provide them with more appropriate clinical, psycholog-
ical, and social care.
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IN THE LAST 2 WEEKS DID YOU FEEL THE FOLLOWING PERCEPTIONS?
You can answer by drawing a cross near the most appropriate answer.1. I felt comfortable even with people I did not know well Very frequently Very much Quite enough A bit Very little Not at all
2. I felt restricted using the means of transportation (bike, car, . . .) Very frequently Very much Quite enough A bit Very little Not at all
3. I succeeded in doing my usual daily activities Very frequently Very much Quite enough A bit Very little Not at all
4. I had to give up some activities I would like to attend
to because of epilepsy
Very frequently Very much Quite enough A bit Very little Not at all5. I had to avoid activities that could provoke a seizure Very frequently Very much Quite enough A bit Very little Not at all
6. I forgot where I put my stuff Very frequently Very much Quite enough A bit Very little Not at all
7. I felt embarrassed about my epilepsy Very frequently Very much Quite enough A bit Very little Not at all
8. I encountered some difﬁculties in concentrating and reading Very frequently Very much Quite enough A bit Very little Not at all
9. I felt people around me did not understand my feelings Very frequently Very much Quite enough A bit Very little Not at all
10. I felt that a seizure had been arriving Very frequently Very much Quite enough A bit Very little Not at all
11. I felt that people around me limited my freedom
in order to try to protect me
Very frequently Very much Quite enough A bit Very little Not at allIN THE LAST 2 WEEKS, DID YOU FEEL THE FOLLOWING PERCEPTIONS?12. I felt scared to go out alone, fearing to have a seizure Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all13. I felt I was different from others, because of the drugs I had to
consume
V
f
ery
requently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all14. I had to be dependent on others in order to move Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all15. I was scared to hurt myself during a seizure Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all16. I felt people around me avoided me because of my epilepsy Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all17. I was scared to have a seizure when I was alone Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all18. I felt my mental activity was particularly slow Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all19. I moved slower than I would like to Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all20. I succeeded in doing my usual work/study/activity
as I would like to do
V
f
ery
requently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all21. I felt people around me underestimated me
because of my epilepsy
V
f
ery
requently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all22. I had to be careful in limiting some activities
(e.g., drinking, eating, smoking)
in order to try to avoid a seizure
V
f
ery
requently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all23. I felt independent in my daily life Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all24. I had to write some notes to remember what I had to do Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all25. Epilepsy was like a ﬁxed idea for me Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all26. I was scared to embarrass people around me Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all27. I had to repeat a sentence twice in order to understand it Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all28. I had some difﬁculties in remembering what people told me Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all29. I was afraid that other people could get scared in case of a seizure Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all30. I often forgot names of other people Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all31. I felt I provoked anxiety in people around me Very
frequently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all32. I had to avoid some (loud, crowded, or too brightly lit) places,
because I was scared these places might provoke a seizure in me
V
f
ery
requently
V
m
ery
uchQuite
enough
A
bit
V
l
ery
ittleNot at
all
A. Piazzini et al. / Epilepsy & Behavior 13 (2008) 119–126 125PLEASE ANSWER THE FOLLOWING SENTENCES AS THEY REFER TO PERCEPTIONS YOU FEEL NOW33. Epilepsy makes it difﬁcult for me to live a normal life Very frequently Very much Quite enough A bit Very little Not at all
34. I am annoyed I have to depend on drugs Very frequently Very much Quite enough A bit Very little Not at all
35. I feel that my life is not so successful as I wish it would be Very frequently Very much Quite enough A bit Very little Not at all
36. I am satisﬁed with the quality of my life Very frequently Very much Quite enough A bit Very little Not at all
37. It is difﬁcult for me to accept my epilepsy Very frequently Very much Quite enough A bit Very little Not at all
38. Epilepsy limits my life Very frequently Very much Quite enough A bit Very little Not at all
39. Epilepsy scares me Very frequently Very much Quite enough A bit Very little Not at all
40. I am scared of the side effects of these drugs Very frequently Very much Quite enough A bit Very little Not at all
41. I am worried about the long-term effects that
epilepsy can have
Very frequently Very much Quite enough A bit Very little Not at all42. Drugs inﬂuence my style of living Very frequently Very much Quite enough A bit Very little Not at all
43. I am very angry because I cannot do anything
because of epilepsy
Very frequently Very much Quite enough A bit Very little Not at all44. It is difﬁcult for me to make plans for the future
because of epilepsyVery frequently Very much Quite enough A bit Very little Not at all45. I am scared to lose my independence because of epilepsy Very frequently Very much Quite enough A bit Very little Not at all
46. I am afraid I can have a seizure next month Very frequently Very much Quite enough A bit Very little Not at allReferences
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